<DOC>
	<DOCNO>NCT00353301</DOCNO>
	<brief_summary>The purpose study test safety efficacy combination erlotinib hydrochloride ( Tarceva™ ) sirolimus ( Rapamune™ ) treatment patient metastatic kidney cancer .</brief_summary>
	<brief_title>Erlotinib Sirolimus Treatment Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>Despite recent advance metastatic renal cell carcinoma remain incurable condition . Currently available treatment high-dose interleukin-2 lead complete response small minority select patient markedly toxic broadly available . FDA-approved multikinase inhibitor ( sorafenib sunitinib malate ) often cause partial transient tumor regression . There standard treatment metastatic renal cell carcinoma patient whose disease progress multikinase inhibitor . The kinase mammalian target rapamycin ( mTOR ) overstimulated subset renal cell carcinoma malignancy block sirolimus lead growth arrest . Erlotinib hydrochloride drug block function epidermal growth factor receptor ( EGFR ) , often express kidney cancer . Sirolimus EGFR inhibitor safely use combination . In vitro experiment show erlotinib enhances sirolimus induce growth impairment panel renal cell carcinoma cell . In present study patient metastatic renal cell carcinoma whose disease progress multikinase inhibitor treat combination erlotinib hydrochloride ( Tarceva™ ) sirolimus ( Rapamune™ ) . This single arm trial placebo drug-based control arm</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Signed informed consent participate study . Histological diagnosis renal cell carcinoma . Age great equal 18 year . Eastern Cooperative Oncology Group ( ECOG ) Performance status 2 better . Life expectancy least 3 month . Failure intolerance previous treatment Sutent® and/or Nexavar® . Most recent systemic treatment least 1 month begin treatment . Most recent local treatment ( surgery irradiation ) &gt; 2 week begin treatment . At least one site measurable disease CT scan MRI ( RECIST criterion ) . Baseline hemoglobin &gt; 9 g/dl , platelet &gt; 100,000/mm3 , absolute neutrophil count ( ANC &gt; 1500/mm3 . Previous treatment Tarceva™ , Iressa™ , Rapamune™ , temsirolimus everolimus . Untreated metastasis central nervous system . Previous solid organ , bone marrow stemcell transplant . Known AIDS HIV infection . Symptomatic poorly control chronic heart failure . Chronic renal failure require dialysis regular basis . Chronic liver failure . Serum aspartate aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) , alkaline phosphatase bilirubin &gt; 1.5 x upper limit normal local laboratory . Pregnant breastfeed woman . Other invasive malignant disease within 5 year ( squamous basal cell carcinoma skin ) . Inability provide informed consent Any serious and/or unstable medical , psychiatric , condition consider P.I . preclude safe reasonably compliant participation protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Carcinoma , Renal Cell</keyword>
	<keyword>Receptor , Epidermal Growth Factor</keyword>
	<keyword>mTOR protein</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Erlotinib</keyword>
</DOC>